Bryan Seiff, MD
Ophthalmology · Dover, DENPI 1720013113
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,550 of the $8,680 with a category attached, or 75.5%. Amgen accounts for 94.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $7,580 and has fallen 95.7% since, to $323 in 2025. Among ophthalmology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $108.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- AbbVie$191
- Galderma Laboratories, L.p.$180
- Medical Device Business Services, Inc.$31
- Merz Pharmaceuticals, LLC$31
- Teleflex LLC$18
- plus $17 from 1 others
What the payments were for
- Consulting fees$451%
- Speaking & faculty fees$6,55075%
- Travel & lodging$6077%
- Food & beverage$1,47817%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 59 | $8,210 |
| AbbVie(2 entities) | 11 | $191 |
| Galderma Laboratories, L.p. | 5 | $180 |
| Medical Device Business Services, Inc. | 2 | $31 |
| Merz Pharmaceuticals, LLC | 1 | $31 |
| Teleflex LLC | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$6,678
How this compares
$8,680 in reported general payments places this provider in the 95th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 450 | $4,624 |
| MoxifloxacinMoxifloxacin Hcl | 126 | $2,897 |
| Prednisolone Acetate | 36 | $2,079 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 133 | $1,454 |
| Bacitracin | 11 | $958 |
| Minocycline Hcl | 13 | $375 |
| Methylprednisolone | 48 | $248 |
| Cephalexin | 18 | $75 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Dover
- David CreechDover$22K
- David LuDover$5K
- Timothy DoyleDover$3K
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Karen RudoMilford$5K
- Scott FudembergRehoboth Beach$5K
- Michael BrosmanWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.